Ashkon Software



NEOT - Neothetics, Inc.

Neothetics, Inc. logo Neothetics, Inc. (NEOT) is a clinical stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. The company's lead product candidate is LIPO-202, which is designed to reduce localized fat deposits and contour specific areas of the body.

LIPO-202 is a first-in-class injectable drug that utilizes a proprietary formulation of salmeterol xinafoate, a long-acting beta-2 adrenergic agonist (LABA), to target adipose tissue. The drug is designed to induce apoptosis, or programmed cell death, in adipocytes (fat cells) while leaving other tissue types unaffected. This results in a reduction in the number and size of adipocytes and an improvement in the contour of the treated area.

The company is initially developing LIPO-202 for the reduction of submental (double chin) fat. The drug has completed a phase II clinical trial, which demonstrated statistically significant reductions in submental fat volume and improvements in patient satisfaction compared to placebo. Neothetics plans to initiate a phase III clinical trial for LIPO-202 in the near future.

In addition to LIPO-202, Neothetics is developing a pipeline of product candidates for the aesthetic market, including drugs for the treatment of cellulite and the improvement of skin laxity.

Neothetics was founded in 7/15/2009 and is headquartered in San Diego, California. The company went public in November 2014 and trades on the NASDAQ under the ticker s




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer